Monotherapy

1. Indicated for overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency

2. 25 mg PO qDay

3. 25 mg dose is typically effective within 8 weeks

4. May increase to 50 mg PO qDay based on individual efficacy and tolerability

Combination with muscarinic antagonist

1.Indicated in combination with the muscarinic antagonist solifenacin succinate for treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency

2. Combination regimen: 25 mg PO qDay plus solifenacin succinate 5 mg PO qDay

3. May increase mirabegron to 50 mg PO qDay after 4-8 weeks based on individual efficacy and tolerability

Renal impairment

1. Mild-to-moderate (eGFR ≥30 mL/min/1.73 m2): No dosage adjustment required

2. Severe (eGFR 15-29 mL/min/1.73 m2): Not to exceed 25 mg/day

3. eGFR <15mL/min/1.73 m2 or on dialysis: Not recommended

Hepatic impairment

1. Mild (Child-Pugh A): No dosage adjustment required

2. Moderate (Child-Pugh B): Not to exceed 25 mg/day for either starting or maximum dose

3. Severe (Child Pugh C): Not recommended